- Conditions
- Liver Transplant; Complications, Vasoplegia
- Interventions
- Angiotensin II, Saline
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1561–1573
of 1,573
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV Infections
- Interventions
- LC002 standard vaccination, LC002 high-dose vaccination, LC002 placebo vaccination
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 5
- States / cities
- Sacramento, California • Chicago, Illinois • Cleveland, Ohio + 1 more
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Rilvegostomig, Volrustomig, Sabestomig, AZD9592, Pembrolizumab, AZD9592 + Rilvegostomig, AZD9592 + Volrustomig, AZD9592 + Sabestomig, AZD9592 + Pembrolizumab
- Biological · Combination Product
- Lead sponsor
- Presage Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 7
- States / cities
- Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 3 more
- Conditions
- Lateral Epicondylitis
- Interventions
- rhPDGF-BB Injection, Placebo
- Drug
- Lead sponsor
- BioMimetic Therapeutics
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 3 more
- Conditions
- Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
- Interventions
- Tcelna, Placebo
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more
- Conditions
- HIV Infections
- Interventions
- Aluminum hydroxide, Lipid A, Monophosphoryl, Lipid A, Liposome-encapsulated monophosphoryl, Syntex adjuvant formulation, MF59, Threonyl Muramyl Dipeptide, rgp120/HIV-1 SF-2, MTP-PE/MF59
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 1996
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Rochester, New York • Seattle, Washington
- Conditions
- Influenza
- Interventions
- Influenza virus vaccine (Fluviral), Saline placebo
- Biological
- Lead sponsor
- ID Biomedical Corporation, Quebec
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 7,400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 43
- States / cities
- Sacramento, California • San Francisco, California • Denver, Colorado + 34 more
- Conditions
- Rheumatic Diseases
- Interventions
- Hepatitis A vaccine, Diphtheria, pertussis, and tetanus booster vaccine
- Biological
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 7
- States / cities
- Northport, Alabama • Riverview, Florida • Boise, Idaho + 4 more
- Conditions
- Wrinkles, Photoaging, Fine Lines
- Interventions
- Onabotulinumtoxin A, Facial Cleanser, Facial Moisturizer, Sunscreen
- Procedure · Combination Product
- Lead sponsor
- Revision Skincare
- Industry
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Fort Lauderdale, Florida • Coralville, Iowa • Columbus, Ohio
- Conditions
- Anemia, Dialysis-dependent Chronic Kidney Disease
- Interventions
- Vadadustat, Epoetin Alfa, Vadadustat TIW
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 41
- States / cities
- Fresno, California • Granada Hills, California • Los Angeles, California + 32 more
- Conditions
- Stroke
- Interventions
- Tissue Plasminogen Activator
- Drug
- Lead sponsor
- University of Iowa
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Macrophage Activation Syndrome
- Interventions
- kineret, placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Rheumatoid Arthritis
- Interventions
- Infliximab
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland